(Q34533371)

English

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

2

object named as

Paul Emery

0 references

object named as

Ahmed A Othman

6

0 references

author name string

Joel M Kremer

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Heidi S Camp

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Alan Friedman

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Li Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Nasser Khan

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Aileen L Pangan

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Steven Jungerwirth

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Edward C Keystone

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

7 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

full work available at URL

http://eprints.whiterose.ac.uk/102783

content deliverer

White Rose Research Online

object has role

published version

1 reference

White Rose Research Online

15 December 2018

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

68

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2867-2877

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Selective JAK inhibitors in development for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Emerging therapies for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Janus kinase inhibitors in autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

The JAK-STAT signaling pathway: input and output integration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5132116

7 July 2018

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39801

21 January 2018

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1002%2FART.39801

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39801

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39801

21 January 2018

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FART.39801

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27389975

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

https://pubmed.ncbi.nlm.nih.gov/27389975

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27389975

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tofacitinib versus methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27389975

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/27389975

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27389975

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27389975

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.39801

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

10.1002/ART.39801

0 references

Dimensions Publication ID

0 references

release_j4hj2peshneydkpv7i3ojatzo4

1 reference

https://api.fatcat.wiki/v0/release/j4hj2peshneydkpv7i3ojatzo4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2-s2.0-84997824455

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34533371&oldid=1835516364"